Anna Passarelli, Vittoria Carbone, Sandro Pignata, Roberta Mazzeo, Domenica Lorusso, Giovanni Scambia, Stefania Canova, Teresa Di Palma, Giulia Tasca, Mara Mantiero, Emanuele Naglieri, Claudia Andreetta, Martina Rauso, Anna Elisabetta Brunetti, Letizia Laera, Chiara Abeni, Giuseppa Scandurra, Anna Rita Gambaro, Alessia Pastore, Carmelo Bengala, Marco Gunnellini, Alberto Farolfi, Maurizio Spinello, Michele Bartoletti
OBJECTIVE: Recurrent gynecological tumors (e.g., endometrial, and ovarian cancers) are incurable diseases; therefore, new treatment options are urgently needed. The PTEN-AKT-PI3K pathway is frequently altered in these tumors, representing a potential treatment target. Alpelisib is an α-specific PI3K inhibitor approved in PIK3CA-mutated advanced breast cancer. We report outcomes from a large series of patients with PIK3CA-mutated gynecological cancers prospectively treated with alpelisib within a controlled program...
March 21, 2024: Gynecologic Oncology